The pediatric asthma treatment market is expected to grow at a CAGR of 3% during the forecast period of 2024 to 2032.  Increases in environmental irritants and awareness of the severity of pediatric asthma contribute to the expansion of the global pediatric asthma treatment market. Several pharmaceutical companies are obtaining FDA approval for asthma medications for children. Through digital platforms, leading companies are organizing educational programs for children and healthcare professionals regarding the proper use of inhalers. Increased participation by a number of large organizations in disseminating information about disease control measures and available asthma treatments is boosting market statistics.

Increase in Pediatric Asthma Prevalence

In recent decades, the prevalence of pediatric asthma has increased globally, making it a significant public health concern. In order to prevent long-term complications in children with asthma, early diagnosis, and treatment are essential. According to the Australian Institute of Health and Welfare, approximately 10% of children aged 0 to 14 years in the country suffered from asthma in 2017 and 2018. According to the World Health Organization (WHO), asthma affected approximately 262 million people worldwide in 2019 and caused 4,555,000 deaths. In the near future, the rise in the global prevalence of pediatric asthma is expected to increase the demand for pediatric asthma treatment. The National Asthma Control Program of the CDC and asthma camps conducted by the Asthma Society of India provide asthma patients with effective disease management techniques that improve their quality of life.

Environmental Irritants Will Drive the Market for Paediatric Asthma Treatments

Smoke and air pollution are environmental irritants that can trigger asthma symptoms in children. Smoke from cigarettes, wood-burning stoves, and fireplaces may contain irritants that aggravate asthma symptoms by inflaming the airways. Similarly, air pollution and industrial emissions can exacerbate the symptoms of asthma in children. To minimize exposure to these triggers, it is recommended to refrain from smoking indoors, spend less time in highly polluted areas, and utilize air purifiers. Additionally, it is essential to collaborate with pediatricians to develop a comprehensive asthma management plan in order to reduce the frequency and severity of symptoms.

Increased Awareness of the Advantages of Long-Term Control Medication

The global pediatric asthma treatment market is segmented by drug type into long-term control medications and quick-relief medications. In 2023, the segment of long-term control medications dominated the global market. Due to their numerous advantages, long-term control medications, such as combination inhalers, are gaining popularity. Inhalers containing both a corticosteroid and a bronchodilator are known as combination inhalers. They are more effective at reducing asthma symptoms than either medication alone.

Increased demand for Inhalers Augmenting Market Progress

The global pediatric asthma treatment market is segmented by form into inhalers, solutions, pills, and injections. In 2023, the inhalation/inhaler segment held the largest share of the global market. Inhalers can be an effective method for managing asthma symptoms. However, it is essential to employ them properly. Inhalers can effectively and efficiently administer medication. They are additionally portable and compact. This is anticipated to stimulate segment expansion.

Increase in Retail Pharmacy Preference for Pediatric Asthma Medications

The market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. In the near future, the retail pharmacies market segment will likely dominate the industry. People prefer retail pharmacies to purchase pediatric asthma medications due to their convenience.

North America Dominates the Global Leader

During the forecast period, North America is anticipated to dominate the global scene. Due to the high prevalence of pediatric asthma in North America, the market in that region is expected to expand at a rapid rate during the forecast period. According to the Centres for Disease Control and Prevention (CDC), approximately 6 million American children aged 0 to 17 suffer from asthma. In light of the region's high prevalence of childhood asthma, a number of companies are developing innovative treatment procedures. This contributes to the expansion of the pediatric asthma treatment market in North America.

During the forecast period, the market for pediatric asthma treatments in Asia Pacific is anticipated to expand at a rapid rate. According to a study published in the Lung India journal, India is home to at least one in ten asthma patients worldwide, with an estimated 1.5 to 2 billion asthma patients. In addition, up to 40.0% of children are diagnosed with asthma at some point. Increased emphasis on respiratory disease management and awareness of pediatric asthma management are driving market growth in the region.

Market Competition to Intensify During the Forecast Period

The global market for pediatric asthma treatment is fragmented, with a large number of local and international players. Expansion of product portfolio and mergers & acquisitions are the primary strategies employed by the most successful businesses.

ECU Health, AstraZeneca PLC, GlaxoSmithKline, CHIESI Farmaceutici S.p.A., Pfizer Inc., Sanofi, Novartis AG, OPKO Health, Inc., Boehringer Ingelheim International GmbH, and Teva Pharmaceutical Industries Ltd. are the leading companies in the pediatric asthma treatment market.

• In 2023, the European Medicines Agency approved Sanofi's Dupixent as an adjunctive maintenance therapy for children (6 to 11 years old) with severe asthma and type 2 inflammation.
• GSK announced in September 2019 that the FDA has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin (IL)-5, for the treatment of severe eosinophilic asthma in children aged six and older.
• In the report on the pediatric asthma treatment market, each of these participants is profiled based on parameters including financial overview, business segments, company overview, recent developments, product portfolio, and business strategies.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pediatric Asthma Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Pediatric Asthma Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Pediatric Asthma Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Pediatric Asthma Treatment market?
• Which is the largest regional market for Pediatric Asthma Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Pediatric Asthma Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Pediatric Asthma Treatment market worldwide?